The Psychotomimetic Properties of 3,4,5-Trimethoxyamphetamine


dl-3,4,5-TRIMETHOXYAMPHETAMINE (dl-TMA), first prepared as a homologue of mescaline in 1947 1, has remained to a large measure unexplored. A single paper has described its effects in human subjects2, demonstrating that the drug allows stroboscope-induced hallucinations at the levels employed, namely, 0.8–2.0 mgm./kgm., orally. In the present work, dl-3,4,5-trimethoxyamphetamine was synthesized by the general method of Ramirez and Burger3 and was chemically identical to that previously described1. Pharmacological similarity was demonstrated by the administration of between 1.6 and 2.0 mgm./kgm. as the hydrochloride, to three adult male subjects. The responses were found to be parallel in intensity and duration to those described earlier2, although the vivid hallucinations reported were not observed.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Hey, P., Quart. J. Pharm. Pharmacol., 20, 129 (1947).

    CAS  Google Scholar 

  2. 2

    Peretz, D. I., Smythies, J. R., and Gibson, W. C., J. Mental Sci., 101, 317 (1955).

    CAS  Article  Google Scholar 

  3. 3

    Ramirez, F. A., and Burger, A., J. Amer. Chem. Soc., 72, 2782 (1950).

    Article  Google Scholar 

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

SHULGIN, A., BUNNELL, S. & SARGENT, T. The Psychotomimetic Properties of 3,4,5-Trimethoxyamphetamine. Nature 189, 1011–1012 (1961).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing